Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis
Trusinska D. et al, (2025), Eclinicalmedicine, 84
The Epidemiology and Clinical Burdens of Human Parainfluenza Virus Infections Amongst Hospitalized Children Under 5 Years of Age in Jordan: A National Multi-Center Cross-Sectional Study
Abu-Helalah M. et al, (2025), Viruses, 17, 170 - 170
The recent landscape of RSV vaccine research.
Kelleher K. et al, (2025), Ther Adv Vaccines Immunother, 13
The Epidemiology and Health Burdens of Influenza Infections Amongst Hospitalized Children Under 5 Years of Age in Jordan: A National Multi-Center Cross-Sectional Study.
Abu-Helalah M. et al, (2024), Vaccines (Basel), 13
The Epidemiology, Clinical, and Economic Burdens of Respiratory Syncytial Virus Infections Amongst Hospitalized Children Under 5 Years of Age in Jordan: A National Multi-Center Cross-Sectional Study
Abu-Helalah M. et al, (2024), Viruses, 16, 1867 - 1867
Prevention of respiratory syncytial virus disease by immunisation.
Benzaken TR. et al, (2024), Archives of disease in childhood. Education and practice edition
What have we learned from animal studies of immune responses to respiratory syncytial virus infection?
Drysdale SB. et al, (2024), J Clin Virol, 175
Epidemiology and Management of Pediatric Group A Streptococcal Pneumonia With Parapneumonic Effusion: An Observational Study.
Lees EA. et al, (2024), Pediatr Infect Dis J, 43, 841 - 850
Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.
Sanchez Clemente N. et al, (2024), Lancet Glob Health, 12, e572 - e588
Nirsevimab for Prevention of RSV Hospitalizations in Infants. Reply.
Faust SN. et al, (2024), N Engl J Med, 390, 1152 - 1153
Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus.
Lin G-L. et al, (2024), Nat Commun, 15
A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.
Johnson M. et al, (2024), J Infect Dis, 229, S112 - S119
External Validation of the Discriminative Validity of the ReSVinet Score and Development of Simplified ReSVinet Scores in Secondary Care.
Sheikh Z. et al, (2024), J Infect Dis, 229, S18 - S24
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Congenital CMV Monthly International Virtual Clinics: A cCMVnet European Initiative.
Gkentzi D. et al, (2024), Pediatr Infect Dis J, 43, e26 - e27
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
Drysdale SB. et al, (2023), N Engl J Med, 389, 2425 - 2435
Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.
Zivanovic N. et al, (2023), Clin Transl Med, 13
Paediatric hospital antimicrobial guidelines: a national UK review.
Shears A. et al, (2023), Arch Dis Child, 108, 946 - 947
National point-prevalence survey of healthcare-associated infections and antimicrobial use: UK-PAS/UKHSA joint call to action for all paediatric services.
Channon-Wells S. et al, (2023), J Antimicrob Chemother, 78, 2392 - 2394